Novavax (NVAX) Announces $388M Funding from CEPI for COVID-19 Vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
May 11, 2020 4:02 PM EDTFunds clinical development of NVX-CoV2373 through Phase 2Supports rapid scale-up of vaccine manufacturingAllows for increased production of Matrix-M adjuvantReserves global large-scale manufacturing capacity
GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax coronavirus vaccine... More
